Last Updated: 17 Sep 2024
Executive Summary
DaVita HealthCare Partners Inc. (DVA) is a leading provider of kidney dialysis services in the United States. The company has a strong financial position with a market capitalization of $13.72 billion, EBITDA of $2.59 billion, and a trailing P/E ratio of 17.4. DaVita has a solid track record of growth, with quarterly earnings and revenue growing by 0.309% and 0.062% year-over-year, respectively. The company's analyst target price is $150.5, and the consensus analyst rating is "Hold."
Company Overview
DaVita HealthCare Partners Inc. provides a range of kidney dialysis services through a network of outpatient dialysis centers in the United States. The company's services include hemodialysis, peritoneal dialysis, and home dialysis. DaVita also provides ancillary services such as laboratory testing, vascular access management, and patient education.
Fundamental Analysis
DaVita HealthCare Partners Inc. has a strong financial position. The company's revenue for the trailing twelve months (TTM) was $12.52 billion, and its gross profit was $3.40 billion. DaVita's diluted EPS for the TTM was $9.40. The company's profit margin is 6.86%, and its operating margin is 16.2%. DaVita's return on assets (ROA) is 6.8%, and its return on equity (ROE) is 45.3%.
Technical Analysis
DaVita HealthCare Partners Inc.'s stock price has been trading in a range between $71.51 and $166.02 over the past 52 weeks. The stock's 50-day moving average is $144.89, and its 200-day moving average is $130.37. The stock's relative strength index (RSI) is 54.67, which indicates that the stock is neither overbought nor oversold.
Short Term Outlook
DaVita HealthCare Partners Inc.'s stock price is currently trading near the top of its 52-week range. The stock's technical indicators are mixed, with the RSI indicating that the stock is neither overbought nor oversold. In the short term, the stock could continue to trade in a range between $144.89 and $166.02.
Long Term Outlook
DaVita HealthCare Partners Inc. is a well-established company with a strong track record of growth. The company's long-term outlook is positive, as the demand for kidney dialysis services is expected to continue to grow in the coming years. The company's analyst target price is $150.5, and the consensus analyst rating is "Hold."
Analyst Recommendations
The consensus analyst rating for DaVita HealthCare Partners Inc. is "Hold." One analyst has a "Buy" rating on the stock, six analysts have a "Hold" rating, and one analyst has a "Sell" rating. The average analyst target price is $150.5.
